Is there still a room for crizotinib in first-line setting in ALK-positive NSCLC patients?

Cover

Previous Page

8 / 39

Next Page

Information

Previous Page

8 / 39

Next Page

Page Background

Toxicity is an issue

Perol - ESMO 2016 * Cho – JTO 2017 (Courtesy of prof. Besse)

ASCEND 8

1 … 3 4 5 6 7 8 9 10 11 12 13 14 … 39